Temgicoluril

From Wikipedia, the free encyclopedia
  (Redirected from )
Temgicoluril
Mebicar.svg
Clinical data
Trade namesAdaptol, Mebicar
Other namesAdaptol; Mebicar; Mebicarum; Mebikar; Tetramethylglycoluril; 1,3,4,6-Tetramethylglycoluril
ATC code
Legal status
Legal status
  • US: Unscheduled; not FDA approved
Pharmacokinetic data
MetabolismGastrointestinal tract: 77–80%
Elimination half-life3 hours[1]
ExcretionUrine: 55–70%
Identifiers
  • 1,3,4,6-Tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H14N4O2
Molar mass198.226 g·mol−1
3D model (JSmol)
  • CN1C2C(N(C1=O)C)N(C(=O)N2C)C
  • InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3
  • Key:XIUUSFJTJXFNGH-UHFFFAOYSA-N

Temgicoluril (INN),[2] also known as tetramethylglycoluril and sold under the brand names Adaptol and Mebicar, is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in Latvia and Russia.[3]

The chemical structure of temgicoluril is similar to metabolites in human body and it doesn't interact with acids, alkali, oxidants and reducing agents. It affects all major neurotransmitter systems.[4]

Temgicoluril has an effect on the structure of limbic–reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin, and adrenergic activity. It decreases the brain norepinephrine levels, exerts no effect on the dopaminergic systems, increases brain serotonin levels, and does not elicit cholinolytic action.[5]

Temgicoluril purportedly has anti-anxiety (anxiolytic) properties.[5][6][7][8][9] It is also used to aid smoking cessation.[3] In addition, temgicoluril may be useful in the treatment of ADHD symptoms.[10] In contrast with typical anxiolytic medications such as benzodiazepines, temgicoluril is non-habit forming, non-sedating, and does not impair motor function.[6][3]

It can be prepared by condensation of N,N-dimethylurea with glyoxal. One publication reported an elegant procedure for doing this. They combined N,N-dimethylurea, glyoxal, and a catalytic amount of phosphoric anhydride in an aqueous solution at room temperature and after sufficient time temgicoluril was conveniently isolated by filtration. The filtrate can be re-used by adding more dimethylurea and glyoxal (no additional catalyst) and obtaining respectable yields, although this requires a longer reaction time.[11]

As of 2021, temgicoluril has not been evaluated by the United States medical system.

Medical uses[]

Temgicoluril is used in Latvia and Russia, as a pharmaceutical drug to treat anxiety and to prevent or reduce anxiety, unrest, fear, internal emotional tension and irritability, reduce neuroses and neurotic disorders, heartburns of non-coronary heart disease origin. These effects are not accompanied with relaxation of muscle tone and impaired coordination of movement, suppression of mental and physical activity, so the drug can be used without interruption of work or school.

Temgicoluril does not have a direct effect on sleep, however, it enhances the effectiveness of sleep medicines and normalizes the course of disturbed sleep. Temgicoluril alleviates or eliminates the manifestations of nicotine dependence that occur after smoking cessation. Temgicoluril does not cause mood swings or euphoria, no habituation and addiction, withdrawal syndrome has been observed.

Side effects[]

Possible and rare side effects may include dizziness, hypotension, indigestion, allergic reactions (itchy skin) after high doses, hypothermia, fatigue. And lowered blood pressure and/or body temperature decreased by 1 to 1.5°C. Blood pressure and body temperature return to normal after completion of treatment.[12]

See also[]

References[]

  1. ^ US 20110070305, Schwarz J, Weisspapir M, "Sustained release pharmaceutical composition containing mebicar" 
  2. ^ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl124.pdf?sfvrsn=6437f035_10&download=true
  3. ^ a b c "Adaptol product summary". Archived from the original on 2013-10-13. Retrieved 2013-05-29.
  4. ^ "Clinical Overview ADAPTOL" (PDF).{{cite web}}: CS1 maint: url-status (link)
  5. ^ a b Val'dman AV, Zaikonnikova IV, Kozlovskaia MM, Zimakova IE (May 1980). "[Characteristics of the psychotropic spectrum of action of mebicar]". Biulleten' Eksperimental'noi Biologii I Meditsiny. 89 (5): 568–70. PMID 6104993.
  6. ^ a b Val'dman AV, Zaikonnikova IV, Kozlovskaya MM, Zimakova IE (1980). "A study of the spectrum of psychotropic action of mebicar". Bulletin of Experimental Biology and Medicine. 89 (5): 621–624. doi:10.1007/BF00835799. S2CID 11343572.
  7. ^ Mkrtchian VR, Kozhokova LZ (2012). "[Adaptol--verges of possible]". Likars'ka Sprava (5): 125–33. PMID 23534281.
  8. ^ Chutko LS, Rozhkova AV, Sidorenko VA, Surushkina SI, Tursunova KB (2012). "[Generalized anxiety disorder: psychosomatic aspects and treatment approaches]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 112 (1): 40–4. PMID 22678674.
  9. ^ Chutko LS, Surushkina SI, Nikishena IS, Iakovenko EA, Anisimova TI, Kuzovenkova MP (2010). "[Asthenic disorders in children]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 110 (11 Pt 1): 26–9. PMID 21183919.
  10. ^ Chutko LS, Surushkina SI, Nikishena IS, Iakovenko EA, Anisimova TI, Sergeev AV (2009). "[Adaptol in the treatment of ADHD]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 109 (8): 45–8. PMID 19738569.
  11. ^ Micheletti, Gabriele; Delpivo, Camilla; Baccolini, Graziano (2013-06-01). "A green synthesis of glycoluril derivatives in aqueous solution with recycle of the waste". Green Chemistry Letters and Reviews. 6 (2): 135–139. doi:10.1080/17518253.2012.718803. ISSN 1751-8253. S2CID 96318579.
  12. ^ "Adaptol (Mebicarum) – State Agency of Medicines of Latvia - Summary of product characteristics". State Agency of Medicines of Latvia (in Latvian).{{cite web}}: CS1 maint: url-status (link)


Retrieved from ""